Horizon Therapeutics plc's star drug Tepezza (teprotumumab) is fully back up and running after a manufacturing supply issue kept it off the market in early 2021. Revenue for the thyroid eye disease (TED) drug is now expected to exceed $1.55bn in full year sales, the company reported on 4 August.
Tepezza generated $453.3m in revenue in the second quarter, exceeding expectations, after the drug was returned to the market in...